EA201270577A1 - Усовершенствованные способы обратной генетики для спасения вирусов - Google Patents

Усовершенствованные способы обратной генетики для спасения вирусов

Info

Publication number
EA201270577A1
EA201270577A1 EA201270577A EA201270577A EA201270577A1 EA 201270577 A1 EA201270577 A1 EA 201270577A1 EA 201270577 A EA201270577 A EA 201270577A EA 201270577 A EA201270577 A EA 201270577A EA 201270577 A1 EA201270577 A1 EA 201270577A1
Authority
EA
Eurasian Patent Office
Prior art keywords
rescue
viruses
reverse genetics
improved methods
genetics
Prior art date
Application number
EA201270577A
Other languages
English (en)
Other versions
EA023811B1 (ru
Inventor
Филип Дормитцер
Бьерн Кайнер
Пирада Суфафифат
Майкл Франти
Питер Мейсон
Дженнифер Улендорфф
Михаил Матросович
Original Assignee
Новартис Аг
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43382472&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EA201270577(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Новартис Аг filed Critical Новартис Аг
Publication of EA201270577A1 publication Critical patent/EA201270577A1/ru
Publication of EA023811B1 publication Critical patent/EA023811B1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5252—Virus inactivated (killed)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16151—Methods of production or purification of viral material

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Pulmonology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Представлен способ спасения вируса с помощью обратной генетики, в котором клетки добавляют после трансфекции.
EA201270577A 2009-10-20 2010-10-20 Способ получения вируса с использованием конструкции, кодирующей вирусную рнк EA023811B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US27948709P 2009-10-20 2009-10-20
PCT/IB2010/054752 WO2011048560A1 (en) 2009-10-20 2010-10-20 Improved reverse genetics methods for virus rescue

Publications (2)

Publication Number Publication Date
EA201270577A1 true EA201270577A1 (ru) 2012-12-28
EA023811B1 EA023811B1 (ru) 2016-07-29

Family

ID=43382472

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201270577A EA023811B1 (ru) 2009-10-20 2010-10-20 Способ получения вируса с использованием конструкции, кодирующей вирусную рнк

Country Status (14)

Country Link
US (2) US8883481B2 (ru)
EP (1) EP2491117B2 (ru)
JP (2) JP5871806B2 (ru)
KR (1) KR20120083480A (ru)
CN (1) CN102741399A (ru)
AU (2) AU2010309404B2 (ru)
CA (1) CA2778332A1 (ru)
EA (1) EA023811B1 (ru)
ES (1) ES2454815T3 (ru)
HK (1) HK1175200A1 (ru)
NZ (1) NZ599479A (ru)
PL (1) PL2491117T3 (ru)
SI (1) SI2491117T1 (ru)
WO (1) WO2011048560A1 (ru)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014141125A2 (en) 2013-03-13 2014-09-18 Novartis Ag Influenza virus reassortment
MX2015016755A (es) 2013-06-06 2016-04-13 Novartis Ag Reagrupamiento del virus de influenza.
EP4299766A3 (en) * 2016-09-27 2024-05-01 Osaka University Method for preparing artificial recombinant rotavirus
CN110029129A (zh) * 2019-03-06 2019-07-19 华南农业大学 一种表达鸡st3gal 1基因的mdck稳转细胞株的构建方法
CN110042084A (zh) * 2019-04-11 2019-07-23 浙江森卫生物医药发展有限公司 一种活病毒流感疫苗的生产方法以及制剂
CN117625688B (zh) * 2024-01-26 2024-04-30 中国农业科学院哈尔滨兽医研究所（中国动物卫生与流行病学中心哈尔滨分中心） B亚型禽偏肺病毒反向遗传操作***及其应用

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2017507C (en) 1989-05-25 1996-11-12 Gary Van Nest Adjuvant formulation comprising a submicron oil droplet emulsion
AU5543294A (en) 1993-10-29 1995-05-22 Pharmos Corp. Submicron emulsions as vaccine adjuvants
DE69510207T3 (de) * 1995-08-09 2007-02-15 Schweiz. Serum- & Impfinstitut Bern Verfahren zur Herstellung von infektiösen minussträngigen RNA-Viren
DE19612966B4 (de) * 1996-04-01 2009-12-10 Novartis Vaccines And Diagnostics Gmbh & Co. Kg MDCK-Zellen und Verfahren zur Vermehrung von Influenzaviren
DE19612967A1 (de) 1996-04-01 1997-10-02 Behringwerke Ag Verfahren zur Vermehrung von Influenzaviren in Zellkultur, sowie die durch das Verfahren erhältlichen Influenzaviren
TW570803B (en) 1997-04-09 2004-01-11 Duphar Int Res Influenza vaccine
US6080725A (en) 1997-05-20 2000-06-27 Galenica Pharmaceuticals, Inc. Immunostimulating and vaccine compositions employing saponin analog adjuvants and uses thereof
JP4625915B2 (ja) * 1998-06-03 2011-02-02 ワイス・ホールディングズ・コーポレイション Ｒｎａウイルスの新規レスキュー方法
GB9916794D0 (en) * 1999-07-16 1999-09-22 Isis Innovation In vitro virus reconstitution
PL355287A1 (en) 1999-09-24 2004-04-05 Smithkline Beecham Biologicals S.A. Intranasal influenza virus vaccine
DE60142506D1 (de) 2000-03-03 2010-08-19 Chemo Sero Therapeut Res Inst In serumfreier kultur verwendbare zelle, kultursuspension und verfahren zur virusproduktion als impfstoff unter verwendung der zelle
BRPI0110607B8 (pt) * 2000-04-28 2021-05-25 St Jude Childrens Res Hospital sistema baseado em plasmídeos, método para produzir um vírion de vírus com fita rna negativa, método para produzir um vírion orthomyxoviridae, método para produzir um vírion influenza, método para produzir um vírion influenzapatogênico, método para preparar uma vacina específica de vírus rna de fita negativa e método para gerar um vírus rna de fita negativa atenuado
KR20090006239A (ko) † 2000-06-23 2009-01-14 와이어쓰 홀딩스 코포레이션 ｃＤＮＡ로 부터 개 홍역 바이러스의 구출
GB0024089D0 (en) 2000-10-02 2000-11-15 Smithkline Beecham Biolog Novel compounds
PT1361890E (pt) 2001-02-23 2011-06-07 Glaxosmithkline Biolog Sa Formulações vacinais de influenza para distribuição intradérmica
EP1361889A1 (en) 2001-02-23 2003-11-19 GlaxoSmithKline Biologicals S.A. Novel vaccine
MY134424A (en) 2001-05-30 2007-12-31 Saechsisches Serumwerk Stable influenza virus preparations with low or no amount of thiomersal
DE10144903A1 (de) * 2001-09-12 2003-03-27 Chiron Behring Gmbh & Co Vermehrung von Viren in Zellkultur
WO2003091401A2 (en) * 2002-04-26 2003-11-06 Medimmune Vaccines, Inc. Multi plasmid system for the production of influenza virus
EP1633860A2 (en) † 2003-06-09 2006-03-15 Wyeth IMPROVED METHOD FOR THE RECOVERY OF NON-SEGMENTED, NEGATIVE-STRANDED RNA VIRUSES FROM cDNA
ES2345492T3 (es) * 2003-12-23 2010-09-24 Medimmune, Llc Sistema multiplasmido para la produccion del virus de la gripe.
KR20070008625A (ko) 2004-04-05 2007-01-17 화이자 프로덕츠 인코포레이티드 미세유체화된 수중유 유화액 및 백신 조성물
WO2005113756A1 (en) 2004-05-14 2005-12-01 Glaxosmithkline Biologicals S.A. Method
CN101094915A (zh) 2004-05-20 2007-12-26 益得生物医学公司 生产流感疫苗的方法
EP1831353B1 (en) 2004-12-23 2012-02-29 MedImmune, LLC Non-tumorigenic mdck cell line for propagating viruses
US7691368B2 (en) 2005-04-15 2010-04-06 Merial Limited Vaccine formulations
US8703095B2 (en) 2005-07-07 2014-04-22 Sanofi Pasteur S.A. Immuno-adjuvant emulsion
AU2006304268B2 (en) 2005-10-14 2011-09-29 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services, Centers For Disease Control And Prevention Rabies virus vector systems and compositions and methods thereof
NZ567817A (en) 2005-11-01 2012-01-12 Novartis Vaccines & Diagnostic Cell-derived viral vaccines with low levels of residual cell DNA by beta-propiolactone treatment
EA014028B1 (ru) 2005-11-04 2010-08-30 Новартис Вэксинс Энд Диагностикс Срл Эмульсии, содержащие свободное поверхностно-активное вещество в водной фазе в качестве адъюванта сплит вакцин против гриппа
FR2896162B1 (fr) 2006-01-13 2008-02-15 Sanofi Pasteur Sa Emulsion huile dans eau thermoreversible
CN101522218B (zh) 2006-10-12 2012-09-26 葛兰素史密丝克莱恩生物有限公司 包含水包油乳液佐剂的疫苗
NZ577405A (en) 2006-12-06 2012-08-31 Novartis Ag Vaccines including antigen from four strains of influenza virus
EP2045323A1 (en) 2007-10-05 2009-04-08 Avir Green Hills Biotechnology Research Development Trade Ag Linear expression constructs for production of influenza virus particles
WO2010046335A1 (en) 2008-10-21 2010-04-29 Crucell Holland B.V. Production of influenza virus by reverse genetics in per.c6 cells under serum free conditions

Also Published As

Publication number Publication date
US20150166966A1 (en) 2015-06-18
CN102741399A (zh) 2012-10-17
CA2778332A1 (en) 2011-04-28
EP2491117A1 (en) 2012-08-29
EA023811B1 (ru) 2016-07-29
AU2015234265A1 (en) 2015-11-05
US20130034582A1 (en) 2013-02-07
EP2491117B1 (en) 2014-01-01
JP5871806B2 (ja) 2016-03-01
PL2491117T3 (pl) 2014-05-30
WO2011048560A1 (en) 2011-04-28
NZ599479A (en) 2013-11-29
AU2010309404A1 (en) 2012-05-17
AU2010309404B2 (en) 2015-07-09
EP2491117B2 (en) 2017-06-28
JP2013507952A (ja) 2013-03-07
ES2454815T3 (es) 2014-04-11
SI2491117T1 (sl) 2014-03-31
KR20120083480A (ko) 2012-07-25
US8883481B2 (en) 2014-11-11
HK1175200A1 (en) 2013-06-28
JP2016104004A (ja) 2016-06-09

Similar Documents

Publication Publication Date Title
CY1121742T1 (el) Αντισωματα s100a4 και θεραπευτικες χρησεις αυτων
BRPI1011886A2 (pt) solução contendo ácido hiplocloroso e métodos do uso do mesmo.
BRPI0919252A2 (pt) Métodos para cultivar células, propagação e purificação de vírus
DK2791367T3 (da) Mutante mikroorganismer til syntetisering af colansyre, mannosylerede og/eller fucosylerede oligosaccharider
TR201910320T4 (tr) Karaciğer organoidi, kullanımları ve elde edilmesine yönelik kültür yöntemi.
BR112014028881A2 (pt) populações de células, banco de células, métodos de obtenção de uma população de células, métodos de identificação de um fator, métodos de seleção, métodos de fornecimento de terapia, populações de hepatócitos e método de obtenção de células
MX339878B (es) Nuevas formas solidas de clorhidrato de bendamustina.
BR112012033538A2 (pt) linhagem celular imortalizada e método de replicação de um vírus
BRPI0924643A2 (pt) método para realizar uma ação de resgate de elevador,e, sistema de elevador.
HUE040024T2 (hu) Porózus membrán újratölthetõ telephez, annak gyártási eljárása és alkalmazása
EA201270577A1 (ru) Усовершенствованные способы обратной генетики для спасения вирусов
BR112012016424A2 (pt) aparelho, e método.
GB201321365D0 (en) Methods for performing patterned chemistry
BR112015008111A2 (pt) célula de levedura geneticamente modificada, e , método para a produção de 3hp.
IN2015KN00073A (ru)
BRPI1008674A2 (pt) Métodos de redução do desenvolvimento de pragas resistentes.
BRPI1013799A2 (pt) eletrodos de desfibrilação.
AP2013007180A0 (en) Truncated HIV envelope proteins (ENV), methods andcompositions related thereto
CY1119959T1 (el) ΔΕΝΔΡΙΤΙΚΑ ΚΥΤΤΑΡΑ ΥΠΟΒΛΗΘΕΝΤΑ ΣΕ ΧΕΙΡΙΣΜΟ ΣΤΗΝ ΠΟΡΕΙΑ ΣΗΜΑΤΟΔΟΤΗΣΗΣ NFkB
WO2013052095A3 (en) Vaccine
WO2012154271A3 (en) Method and cells for identifying rig-i pathway regulators
SG195170A1 (en) Methods of treating or preventing rheumatic disease
EP2537961A4 (en) ELECTRODE BASE, NEGATIVE ELECTRODE FOR ELECTROLYSIS OF AQUEOUS SOLUTION USING THE SAME, METHOD FOR PRODUCING THE ELECTRODE BASE, AND PROCESS FOR PRODUCING THE NEGATIVE ELECTRODE FOR ELECTROLYSIS OF AQUEOUS SOLUTION
EA201100902A1 (ru) Новый способ получения рнк-вируса
PL2821458T3 (pl) Roztwór elektrolitu, sposób jego drukowania i uzyskany stały elektrolit

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG MD TJ TM

PC4A Registration of transfer of a eurasian patent by assignment
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): RU